Provider notes

• NMUH:
  
  • Restricted for patients allergic to Warfain only.
  • Check MHRA Drug Safety Updates
• RFL:
  
  • Restricted for patients allergic to warfarin only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Rivaroxaban is the preferred DOAC for VTE, apixaban may be considered in line with NCL JFC Position Statement (JFC February 2020). 

Provider notes

• NMUH:
  
  • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
  • See JFC note above
  • Check MHRA Drug Safety Update
  • A referral form must be completed by Authorised Teams/ Haematology team to initiate a DOAC
  • A GP notification form must be completed and sent to the GP for each patient newly started on a DOAC
  • A copy of the above forms (referral form and GP notification form) must be sent to the anticoagulant clinic
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • 2nd Choice DOAC - For Atrial Fibrillation / Stroke prevention.

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Approved for (JFC January 2019):

• Multiple myeloma starting chemotherapy with thalidomide, lenalidomide or pomalidomide who would previously have received LMWH
• Newly diagnosed multiple myeloma with additional VTE risk factor

Dose is 2.5mg twice-daily.

Provider notes

• NMUH:
• Non-formulary
• RFL:
• Approved for thromboprophylaxis for patients have thalidomide, lenalidomide, pomalidomide
• RNOH:
• Non-formulary
• UCLH:
• WH:
• As above

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibity criteria

Not preferred treatment for VTE (JFC February 2020; see Position Statement below).

Provider notes

• NMUH:
  
  • As per NICE TA157, TA249, TA327 (not preferred)
  • Follow NCL DOAC prescribing guide
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • Follow NCL DOAC prescribing guide
• UCLH:
• WH:
  
  • Restricted for use as thromboprophylaxis after elective hip and knee surgery

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Not preferred treatment for VTE (JFC February 2020; see Position Statement below).

Provider notes

• NMUH:
  
  • As per NICE TA354 (not preferred) and TA355
  • Follow NCL DOAC prescribing guide
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Not to be used for initiation of therapy.

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Should only be used in patients who are allergic to warfarin.
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

See NICE TA for eligibility criteria

Preferred DOAC for treatment of VTE (JFC February 2020; see Position Statement below).

Provider notes

• NMUH:
  
  • TA170, TA261 (preferred choice), TA265, TA287 (preferred choice), TA335
  • Follow NCL DOAC prescribing guide
• RFL:
  
  • As per NICE guidance
  • Follow NCL DOAC prescribing guide
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • 1st Choice - For Atrial Fibrillation / Stroke prevention.

Provider notes

• NMUH:No restriction stated
  • Check MHRA drug safety update
• RFL:
  • No restriction stated
• RNOH:
  • No restriction stated
• UCLH:
• WH:
  • No restriction stated